<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019927</url>
  </required_header>
  <id_info>
    <org_study_id>12-232</org_study_id>
    <nct_id>NCT02019927</nct_id>
  </id_info>
  <brief_title>Electric Stimulation of the Eye to Improve Vision After Trauma</brief_title>
  <acronym>TES</acronym>
  <official_title>Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Function After Ocular Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcorneal Electrical Stimulation (TES) using the &quot;OkuStim®&quot; device delivers electrical
      impulses to damaged and/or diseased photoreceptor cells. This electric stimulation of the
      retina may help to preserve visual acuity and/or the visual field.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The finely detailed, precise anatomy of the retina and optic nerve capture light impulses
      from the environment through a biochemical process and then transmit these images to the
      brain via electrical impulses conducted from the inner retina to the optic nerve and
      ultimately to the occipital cortex.

      In the human eye, three types of specialized ganglion cells transmit electrical impulses to
      the brain. Among these three cell populations are rod and cone cells, which participate in
      the photo-transduction step of light perception, along with other light sensitive ganglion
      cells. It is a system whereby the photosensitive pigment rhodopsin (or one of its analogs)
      rearranges in response to light, and this change in chemical structure fires electrical
      impulses to the brain which in turn interprets the incoming impulses as a visual image.

      Transcorneal Electrical Stimulation (TES) using the &quot;OkuStim®&quot; device delivers electrical
      impulses to damaged and/or diseased photoreceptor cells. This electric stimulation of the
      retina may help to preserve VA and/or the visual field.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Acuity</measure>
    <time_frame>Change from Baseline (week 1) to 1-week post initial treatment (week 8)</time_frame>
    <description>The primary outcomes are change in high-contrast LogMar VA from baseline (week 1) to initial post treatment (week 8). Participants read letters from a chart and receive 1 point for each letter correctly identified. Scores are converted to logMAR scale and analyzed for changes in visual acuity. Improvement in visual acuity is defined as a decrease in logMAR of 0.2 or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-Ocular Pressure (IOP)</measure>
    <time_frame>Change from Baseline (week 1) to 1-week post initial treatment (week 8)</time_frame>
    <description>Measured by Applanation (Galdmann) Tonometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field Mean Deviation</measure>
    <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
    <description>The Humphrey 24-2 Swedish Interactive Threshold Algorithm Standard perimeter was used to test visual field. Reported values are a change from baseline to 1-week post initial treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Superior Quadrant</measure>
    <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
    <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Nasal Quadrant</measure>
    <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
    <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Inferior Quadrant</measure>
    <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
    <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Temporal Quadrant</measure>
    <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
    <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Center Quadrant</measure>
    <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
    <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute's Visual Functioning Questionnaire - 25</measure>
    <time_frame>Change from Baseline to 1 - week post initial treatment</time_frame>
    <description>Test to measure Unweighted of scores within test ranging from 0-100 with higher scores meaning better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modality Testing</measure>
    <time_frame>Change from Baseline to 1 - week post initial treatment</time_frame>
    <description>Scores range from 0-110 with higher scores meaning better visual information processing speed</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)</condition>
  <condition>Trauma</condition>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>Non-arthritic ischemic optic neuropathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocular Trauma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham - Non-arthritic ischemic optic neuropathy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham - Multiple Sclerosis</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham - Ocular Trauma</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcorneal Electrical Stimulation</intervention_name>
    <description>The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
    <arm_group_label>Non-arthritic ischemic optic neuropathy</arm_group_label>
    <arm_group_label>Ocular Trauma</arm_group_label>
    <other_name>TES</other_name>
    <other_name>OkuVision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham</description>
    <arm_group_label>Sham - Multiple Sclerosis</arm_group_label>
    <arm_group_label>Sham - Non-arthritic ischemic optic neuropathy</arm_group_label>
    <arm_group_label>Sham - Ocular Trauma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You are 18 years or older.

          -  You have sustained trauma (more than 3 months before this study) OR been diagnosed
             with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (more than 6 months
             before this study) OR been diagnosed with Multiple Sclerosis (MS) and suffered visual
             loss (more than 3 months before this study).

          -  You are willing and able to give written informed consent.

          -  You are able to commit to enrolling in the study during the full time period of up to
             6 months.

        Exclusion Criteria:

          -  You have any other significant ophthalmologic disease or condition (such as glaucoma,
             retinal degeneration, proliferative diabetic retinopathy, +/- six diopters of myopia,
             retinal detachment, exudative age-related macular degeneration).

          -  You have amblyopia (lazy eye) in affected eye, previously diagnosed.

          -  You are participating in any other interventional clinical trial.

          -  If you are pregnant OR a woman with childbearing potential who is unwilling to use
             medically acceptable means of birth control for study duration OR woman unwilling to
             perform a pregnancy test at study entry/screening.

          -  You are unable to give signed consent due to memory, medical, communication, language,
             or mental health problems.

          -  You are less than 18 years old.

          -  You are unable or unwilling to complete the evaluation or questionnaire.

          -  Visual acuity better than 20/40

          -  Inability to detect phosphenes during threshold detection

          -  You are on seizure medications, or have a history of epilepsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Haller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <results_first_submitted>September 17, 2019</results_first_submitted>
  <results_first_submitted_qc>January 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Julia Haller</investigator_full_name>
    <investigator_title>Evaluation of the Effectiveness of Transcorneal Electrical Stimulation to Improve Visual Function Following Ocular Trauma</investigator_title>
  </responsible_party>
  <keyword>NAION</keyword>
  <keyword>Decreased vision</keyword>
  <keyword>Eye trauma</keyword>
  <keyword>TES</keyword>
  <keyword>Electrical stimulation</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Optic Neuritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02019927/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-arteritic Ischemic Optic Neuropathy</title>
          <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="P2">
          <title>Non-arteritic Ischemic Optic Neuropathy (NAION) Sham</title>
          <description>Sham treatment for Non-arteritic ischemic optic neuropathy group</description>
        </group>
        <group group_id="P3">
          <title>Multiple Sclerosis</title>
          <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="P4">
          <title>Multiple Sclerosis Sham</title>
          <description>Sham treatment for optic neuritis with Multiple Sclerosis group</description>
        </group>
        <group group_id="P5">
          <title>Ocular Trauma</title>
          <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="P6">
          <title>Ocular Trauma Sham</title>
          <description>Sham treatment for ocular trauma group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-arteritic Ischemic Optic Neuropathy</title>
          <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="B2">
          <title>Non-arteritic Ischemic Optic Neuropathy Sham</title>
          <description>Sham comparator for the Non-arteritic ischemic optic neuropathy group</description>
        </group>
        <group group_id="B3">
          <title>Multiple Sclerosis</title>
          <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="B4">
          <title>Multiple Sclerosis Sham</title>
          <description>Sham comparator for the multiple sclerosis group</description>
        </group>
        <group group_id="B5">
          <title>Ocular Trauma</title>
          <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="B6">
          <title>Ocular Trauma Sham</title>
          <description>Sham comparator for the ocular trauma group</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="8.8"/>
                    <measurement group_id="B2" value="66" spread="7.4"/>
                    <measurement group_id="B3" value="40.6" spread="9.7"/>
                    <measurement group_id="B4" value="41" spread="9.2"/>
                    <measurement group_id="B5" value="49.2" spread="14.2"/>
                    <measurement group_id="B6" value="45.5" spread="13.2"/>
                    <measurement group_id="B7" value="50.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Acuity</title>
        <description>The primary outcomes are change in high-contrast LogMar VA from baseline (week 1) to initial post treatment (week 8). Participants read letters from a chart and receive 1 point for each letter correctly identified. Scores are converted to logMAR scale and analyzed for changes in visual acuity. Improvement in visual acuity is defined as a decrease in logMAR of 0.2 or more.</description>
        <time_frame>Change from Baseline (week 1) to 1-week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to Multiple Sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Acuity</title>
          <description>The primary outcomes are change in high-contrast LogMar VA from baseline (week 1) to initial post treatment (week 8). Participants read letters from a chart and receive 1 point for each letter correctly identified. Scores are converted to logMAR scale and analyzed for changes in visual acuity. Improvement in visual acuity is defined as a decrease in logMAR of 0.2 or more.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" lower_limit="-0.30" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.23" upper_limit="-0.05"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-0.22" upper_limit="0.06"/>
                    <measurement group_id="O4" value="-0.06" lower_limit="-0.25" upper_limit="0.13"/>
                    <measurement group_id="O5" value="-0.29" lower_limit="-0.45" upper_limit="-0.12"/>
                    <measurement group_id="O6" value="-0.05" lower_limit="-0.3" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra-Ocular Pressure (IOP)</title>
        <description>Measured by Applanation (Galdmann) Tonometry method</description>
        <time_frame>Change from Baseline (week 1) to 1-week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - Non-arteritic Ischemic Optic Neuropathy (NAION)</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis (MS)</title>
            <description>Sham treatment of decreased vision due to MS</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-Ocular Pressure (IOP)</title>
          <description>Measured by Applanation (Galdmann) Tonometry method</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" lower_limit="-0.99" upper_limit="0.34"/>
                    <measurement group_id="O2" value="-1.13" lower_limit="-2.06" upper_limit="-0.20"/>
                    <measurement group_id="O3" value="-0.27" lower_limit="-3.26" upper_limit="2.72"/>
                    <measurement group_id="O4" value="0.52" lower_limit="-2.77" upper_limit="3.81"/>
                    <measurement group_id="O5" value="0.52" lower_limit="-1.57" upper_limit="2.6"/>
                    <measurement group_id="O6" value="-0.57" lower_limit="-4.78" upper_limit="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Field Mean Deviation</title>
        <description>The Humphrey 24-2 Swedish Interactive Threshold Algorithm Standard perimeter was used to test visual field. Reported values are a change from baseline to 1-week post initial treatment.</description>
        <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Field Mean Deviation</title>
          <description>The Humphrey 24-2 Swedish Interactive Threshold Algorithm Standard perimeter was used to test visual field. Reported values are a change from baseline to 1-week post initial treatment.</description>
          <units>Decibels (dB)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="0.72" upper_limit="2.25"/>
                    <measurement group_id="O2" value="2.09" lower_limit="1.03" upper_limit="3.15"/>
                    <measurement group_id="O3" value="1.31" lower_limit="-0.94" upper_limit="3.55"/>
                    <measurement group_id="O4" value="0.96" lower_limit="-2.21" upper_limit="4.13"/>
                    <measurement group_id="O5" value="1.70" lower_limit="0.23" upper_limit="3.18"/>
                    <measurement group_id="O6" value="0.25" lower_limit="-1.98" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Superior Quadrant</title>
        <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
        <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Superior Quadrant</title>
          <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
          <units>um</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-9.92" upper_limit="8.52"/>
                    <measurement group_id="O2" value="12.41" lower_limit="-0.66" upper_limit="25.47"/>
                    <measurement group_id="O3" value="-3.80" lower_limit="-12.97" upper_limit="5.37"/>
                    <measurement group_id="O4" value="-5.97" lower_limit="-18.86" upper_limit="6.92"/>
                    <measurement group_id="O5" value="0.37" lower_limit="-2.13" upper_limit="2.87"/>
                    <measurement group_id="O6" value="1.42" lower_limit="-2.33" upper_limit="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Nasal Quadrant</title>
        <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
        <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Nasal Quadrant</title>
          <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
          <units>um</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" lower_limit="-2.64" upper_limit="1.69"/>
                    <measurement group_id="O2" value="-1.24" lower_limit="-4.30" upper_limit="1.82"/>
                    <measurement group_id="O3" value="-3.60" lower_limit="-9.33" upper_limit="2.12"/>
                    <measurement group_id="O4" value="0.28" lower_limit="-7.69" upper_limit="8.26"/>
                    <measurement group_id="O5" value="0.49" lower_limit="-1.66" upper_limit="2.65"/>
                    <measurement group_id="O6" value="-1.36" lower_limit="-4.59" upper_limit="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Inferior Quadrant</title>
        <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
        <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Inferior Quadrant</title>
          <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
          <units>um</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-1.28" upper_limit="1.21"/>
                    <measurement group_id="O2" value="-0.64" lower_limit="-2.40" upper_limit="1.12"/>
                    <measurement group_id="O3" value="-2.37" lower_limit="-6.94" upper_limit="2.19"/>
                    <measurement group_id="O4" value="1.07" lower_limit="-5.23" upper_limit="7.37"/>
                    <measurement group_id="O5" value="0.57" lower_limit="-2.03" upper_limit="3.16"/>
                    <measurement group_id="O6" value="-1.53" lower_limit="-5.51" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Temporal Quadrant</title>
        <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
        <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Temporal Quadrant</title>
          <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
          <units>um</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="-2.43" upper_limit="6.73"/>
                    <measurement group_id="O2" value="-0.64" lower_limit="-2.40" upper_limit="1.12"/>
                    <measurement group_id="O3" value="-0.49" lower_limit="-1.62" upper_limit="0.64"/>
                    <measurement group_id="O4" value="1.07" lower_limit="-5.23" upper_limit="7.37"/>
                    <measurement group_id="O5" value="-0.35" lower_limit="-1.71" upper_limit="1.00"/>
                    <measurement group_id="O6" value="-1.53" lower_limit="-5.51" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Center Quadrant</title>
        <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
        <time_frame>Change from Baseline (week 1) to 1 - week post initial treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Center Quadrant</title>
          <description>Assessed the change in thickness of the retinal nerve fiber layer 1-week post treatment compared to baseline</description>
          <units>um</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-4.43" upper_limit="4.23"/>
                    <measurement group_id="O2" value="3.89" lower_limit="-1.79" upper_limit="9.55"/>
                    <measurement group_id="O3" value="-2.83" lower_limit="-7.63" upper_limit="1.97"/>
                    <measurement group_id="O4" value="-1.07" lower_limit="-7.34" upper_limit="5.19"/>
                    <measurement group_id="O5" value="-0.62" lower_limit="-2.14" upper_limit="0.91"/>
                    <measurement group_id="O6" value="-0.42" lower_limit="-2.50" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Eye Institute's Visual Functioning Questionnaire - 25</title>
        <description>Test to measure Unweighted of scores within test ranging from 0-100 with higher scores meaning better outcome</description>
        <time_frame>Change from Baseline to 1 - week post initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>National Eye Institute's Visual Functioning Questionnaire - 25</title>
          <description>Test to measure Unweighted of scores within test ranging from 0-100 with higher scores meaning better outcome</description>
          <units>score on a scale - change from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" lower_limit="-2.41" upper_limit="1.24"/>
                    <measurement group_id="O2" value="0.16" lower_limit="-2.40" upper_limit="2.72"/>
                    <measurement group_id="O3" value="4.59" lower_limit="-2.55" upper_limit="11.73"/>
                    <measurement group_id="O4" value="4.57" lower_limit="-5.08" upper_limit="14.22"/>
                    <measurement group_id="O5" value="3.64" lower_limit="-1.40" upper_limit="8.67"/>
                    <measurement group_id="O6" value="5.27" lower_limit="-2.51" upper_limit="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symbol Digit Modality Testing</title>
        <description>Scores range from 0-110 with higher scores meaning better visual information processing speed</description>
        <time_frame>Change from Baseline to 1 - week post initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-arteritic Ischemic Optic Neuropathy</title>
            <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O2">
            <title>Sham - NAION</title>
            <description>Sham treatment of decreased vision due to NAION</description>
          </group>
          <group group_id="O3">
            <title>Multiple Sclerosis</title>
            <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O4">
            <title>Sham - Multiple Sclerosis</title>
            <description>Sham treatment of decreased vision due to multiple sclerosis</description>
          </group>
          <group group_id="O5">
            <title>Ocular Trauma</title>
            <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
          </group>
          <group group_id="O6">
            <title>Sham - Ocular Trauma</title>
            <description>Sham treatment of decreased vision due to ocular trauma</description>
          </group>
        </group_list>
        <measure>
          <title>Symbol Digit Modality Testing</title>
          <description>Scores range from 0-110 with higher scores meaning better visual information processing speed</description>
          <units>score on a scale - change from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-2.42" upper_limit="2.37"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-3.52" upper_limit="3.50"/>
                    <measurement group_id="O3" value="2.98" lower_limit="-1.70" upper_limit="7.66"/>
                    <measurement group_id="O4" value="-0.77" lower_limit="-6.48" upper_limit="4.94"/>
                    <measurement group_id="O5" value="4.08" lower_limit="-2.19" upper_limit="10.36"/>
                    <measurement group_id="O6" value="6.14" lower_limit="-3.58" upper_limit="15.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-arteritic Ischemic Optic Neuropathy</title>
          <description>Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="E2">
          <title>Sham - Non-arteritic Ischemic Optic Neuropathy</title>
          <description>Sham treatment of decreased vision due to NAION</description>
        </group>
        <group group_id="E3">
          <title>Multiple Sclerosis</title>
          <description>Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="E4">
          <title>Sham - Multiple Sclerosis</title>
          <description>Sham treatment of decreased vision due to Multiple Sclerosis</description>
        </group>
        <group group_id="E5">
          <title>Ocular Trauma</title>
          <description>Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
Transcorneal Electrical Stimulation: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.</description>
        </group>
        <group group_id="E6">
          <title>Sham - Ocular Trauma</title>
          <description>Sham treatment of decreased vision due to ocular trauma</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Minor ocular surface irritation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ann Murchison MD</name_or_title>
      <organization>Will Eye Hopsital</organization>
      <phone>267-733-9617</phone>
      <email>Visionresearch@willseye.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

